Theory and Practice of Conventional Adventitious Virus Testing

References

1. 1.↵
   European Directorate for the Quality of Medicines (EDQM). Tests for extraneous agents in viral vaccines for human use. Chapter 2.6.16. European Pharmacopoeia 5.0, 2005.
2. 2.↵
   Center for Biologics Evaluation and Research (CBER). Guidance for industry: Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. Rockville, MD, USA, 2010.
3. 3.↵
   1. Americo J. L.,
   2. Moss B.,
   3. Earl P. L.

   Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models. J. Virol. 2010, 84 (16): 8172–8180.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Kraemer B.,
   2. Ruebmann P. K.,
   3. Duchow K.,
   4. Cussler K.

   Fremdvirusausschluß in Lebendimpfstoffen. ALTEX 1998, 15, 43–45.

   OpenUrlPubMed
5. 5.↵
   1. Heiss B. L.,
   2. Maximova O. A.,
   3. Pletnev A. G.

   Insertion of microRNA targets into the flavivirus genome alters its highly neurovirulent phenotype. J. Virol. 2010, 85 (4), 1464–1472.

   OpenUrlPubMed
6. 6.↵
   1. Bennett R. S.,
   2. Cress C. M.,
   3. Ward J. M.,
   4. Firestone C. Y.,
   5. Murphy B. R.,
   6. Whitehead. S. S.

   La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys. Virol. J. 2008, 5, 25.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Rong X.,
   2. Xiang R. L.,
   3. Chu M. P.,
   4. Wu R. Z.,
   5. Chen Q.,
   6. Xu Q.,
   7. Zhang Y. H.

   Effects of hemoglobin oxygenase-1 inhibitor zinc protoporphyrin IX on acute viral myocarditis in mice. Zhonghua Er Ke Za Zhi 2007, 45 (12), 893–897. [Article in Chinese. Detailed abstract available under http://www.ncbi.nlm.nih.gov/pubmed/18339274.]

   OpenUrlPubMed
8. 8.↵
   1. Yauch L. E.,
   2. Shresta S.

   Mouse models of dengue virus infection and disease. Antiviral Res. 2008, 80 (2), 87–93.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Tan G. K.,
   2. Ng J. K.,
   3. Trasti S. L.,
   4. Schul W.,
   5. Yip G.,
   6. Alonso S.

   A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS. Negl. Trop. Dis. 2010, 27, e672.

   OpenUrl
10. 10.↵
    1. Horzinek M. C.

    Haemagglutinationstest. Chapter 1.1.2.2. In: Kompendium der Allgemeinen Virologie, 2nd Ed.; Verlag Paul Parey, Berlin, 1985; p 24.
11. 11.↵
    1. Mayr A.,
    2. Bachmann P.,
    3. Bibrack B.,
    4. Wittmann G.

    Haemagglutinationshemmungsreaktion (HAH). In Virologische Arbeitsmethoden; Band II, Chapter 2. G. Fischer Verlag: Stuttgart, New York, 1977; pp 207–223.
12. 12.↵
    1. Barta V.,
    2. Springer W. T.,
    3. Millar D. L.

    A comparison of avian and mammalian cell cultures for the propagation of avian reovirus WVU 2937. Avian Dis. 1984, 28 (1), 216–223.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Sahu S. P.,
    2. Olson N. O.

    Comparison of characteristics of avian reovirus isolated from the digestive and respiratory tract with virus isolated from the synovia. Am. J. Vet. Res. 1975, 36 (6), 847–850.

    OpenUrlPubMed
14. 14.↵
    1. Jones R. C.,
    2. Al Afaleq A. I.

    Different sensitivities of Vero cells from two sources to avian reoviruses. Res. Vet. Sci. 1990, 48 (3), 379–380.

    OpenUrlPubMed
15. 15.↵
    1. Heilbronn R.,
    2. Albrecht I.,
    3. Stephan S.,
    4. Bürkle A.,
    5. zur Hausen H.

    Human cytomegalovirus induces JC virus DNA replication in human fibroblasts. Proc. Natl. Acad. Sci. USA 1993, 90 (23), 11406–11410.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Duizer E.,
    2. Schwab K. J.,
    3. Neill F. H.,
    4. Atmar R. L.,
    5. Koopmans M. P. G.,
    6. Estes M. K.

    Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 2004, 85, 79–87.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Malik Y. S.,
    2. Maherchandani S.,
    3. Allwood P. B.,
    4. Goyal S. M.

    Evaluation of animal origin cell cultures for in vitro cultivation of noroviruses. J. Appl. Res. 2005, 5 (2), 312–317.

    OpenUrl
18. 18.↵
    1. Moore W. A.

    Experience in cell line testing. Dev. Biol. Stand. 1992, 76, 51–56.

    OpenUrlPubMed
19. 19.↵
    1. Kravchenko A. T.,
    2. Tsetlin E. M.,
    3. Omelchenko T. N.

    Rational method of producing sera with high titers of virus neutralizing antibodies. Zh. Mikrobiol. Epidemiol. Immunobiol. 1997, 1, 41–45.

    OpenUrl
20. 20.↵
    European Directorate for the Quality of Medicines (EDQM). Influenza vaccine (surface antigen, inactivated, prepared in cell cultures). Monograph 2149, Supp. 5.5, European Pharmacopoeia, Strasbourg, 2006.
21. 21.↵
    1. Ill C. R.,
    2. Dehghani H.

    Risk reduction in biotherapeutic products. Curr. Opin. Drug Discov. Devel. 2009, 12 (2), 296–304.

    OpenUrlPubMed
22. 22.↵
    1. Onions D.,
    2. Kolman J.

    Massively parallel sequencing, a new method for detecting adventitous agents. Biologicals 2010, 38 (3), 377–380.

    OpenUrlPubMed
23. 23.↵
    1. Victoria J. G.,
    2. Wang C.,
    3. Jones M. S.,
    4. Jaing C.,
    5. McLoughlin K.,
    6. Gardner S.,
    7. Delwart E. L.

    Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J. Virol. 2010, 84 (12), 6033–6040.

    OpenUrlAbstract/FREE Full Text